Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

被引:108
作者
Tay, EH
Grant, PT
Gebski, V
Hacker, NF
机构
[1] Univ New S Wales, Royal Hosp Women, Dept Obstet & Gynaecol, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia
[2] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW 2006, Australia
关键词
D O I
10.1016/S0029-7844(02)01977-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To review our experience with secondary cytoreductive surgery for recurrent epithelial ovarian cancer with regard to its feasibility, morbidity, mortality, patient selection, and survival. METHODS: Forty-six patients who underwent secondary cytoreductive surgery at the Royal Hospital for Women, Sydney, between July 1988 and October 1996 were retrospectively reviewed. The mean age at surgery was 50.3 years, and the median disease-free interval was 26 months. Eighty-nine percent of patients had a disease-free interval of at least 12 months. Twenty-five patients (54%) had localized disease at the time of surgery. Univariate survival outcomes were analyzed using the log rank test, and survival curves were calculated using the method of Kaplan-Meier. RESULTS: Two patients (4%) were inoperable and 19 patients (41%) were cytoreduced to no macroscopic disease. There was one postoperative death (2%), and four patients (8.7%) had significant postoperative morbidity. With a median follow-up of 88 months, the overall median survival was 22.5 months. Patients with a disease-free interval of less than 12 months after their initial treatment had a median survival of 6 months, compared with 11 months if the disease-free interval was 12-24 months and 39 months for those with a disease-free interval of 24 months or more (P = .001, log rank). Patients who had any residual disease had a median survival of 11 months, whereas those with no residual disease had a median survival of 38 months (P = .002, log rank). CONCLUSION: For carefully selected patients with recurrent epithelial ovarian cancer: 1) complete surgical resection is feasible more commonly than with primary cytoreduction, 2) serious morbidity and mortality are acceptable, and 3) significant survival benefit accrues when a) all macroscopic disease can be resected, or b) the disease-free interval is 24 months or more. (Obstet Gynecol 2002;99:1008-13. (C) 2002 by the American College of Obstetricians and Gynecologists).
引用
收藏
页码:1008 / 1013
页数:6
相关论文
共 24 条
[1]  
BEREK JS, 1983, OBSTET GYNECOL, V61, P189
[2]  
BEREK JS, 1984, OBSTET GYNECOL, V64, P207
[3]  
Bristow RE, 1996, CANCER, V78, P2049, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2049::AID-CNCR4>3.0.CO
[4]  
2-J
[5]  
BURKE TW, 1994, OBSTET GYN CLIN N AM, V21, P167
[6]  
CHILDERS JM, 1994, OBSTET GYNECOL, V84, P765
[7]  
EISENKOP SM, 1995, CANCER, V76, P1606, DOI 10.1002/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO
[8]  
2-H
[9]  
GERHENSON D, 1985, CANCER, V55, P1129
[10]  
HACKER NF, 1993, ANN ONCOL S4, V4, pS17